As Novo Nordisk begins PhII sickle cell trial, it snags a later-stage blood
Lumakras, Amgen’s groundbreaking KRAS drug, was approved on data from an open-label, single-arm study suggesting, among other things, median progression-free survival of 6.8 months for patients with…